Who owns ENLIVEN THERAPEUTICS INC?
- Ticker: ELVN
- CUSIP Number: 29337e102
Tip: Access positions for across all investors
Analyze quarterly positions in Enliven Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Enliven Therapeutics stock
Who bought or sold ENLIVEN THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OrbiMed Advisors | 9.0M | $158M | 0% | Mar 2024 |
|
| FMR | 6.2M | $110M | 70% | Mar 2024 |
|
| VR Adviser | 4.0M | $71M | 36% | Mar 2024 |
|
| Commodore Capital | 4.0M | $70M | 37% | Mar 2024 |
|
| 5AM Venture Management | 3.8M | $68M | -26% | Mar 2024 |
|
| Fairmount Funds Management | 3.2M | $56M | 50% | Mar 2024 |
|
| Citadel Advisors | 2.4M | $41M | -2% | Mar 2024 |
|
| RA Capital Management | 2.1M | $37M | 0% | Mar 2024 |
|
| BlackRock | 1.8M | $32M | 16% | Mar 2024 |
|
| Logos Global Management | 1.6M | $26M | 413% | Mar 2024 |
|
| Vanguard Group | 1.2M | $21M | -4% | Mar 2024 |
|
| Henderson Group | 714k | $13M | 75% | Mar 2024 |
|
| Boxer Capital | 671k | $12M | 4% | Mar 2024 |
|
| Geode Capital Management | 476k | $8.4M | 10% | Mar 2024 |
|
| Rock Springs Capital Management | 429k | $7.5M | 100% | Mar 2024 |
|
| Woodline Partners | 396k | $7.0M | 0% | Mar 2024 |
|
| Northern Trust | 219k | $3.8M | 12% | Mar 2024 |
|
| Charles Schwab Investment Management | 159k | $2.8M | 0% | Mar 2024 |
|
| HighVista Strategies | 127k | $2.2M | 2% | Mar 2024 |
|
| Baker Bros. Advisors | 115k | $2.0M | 100% | Mar 2024 |
|
| Nuveen Asset Management | 83k | $1.5M | -5% | Mar 2024 |
|
| Bank of New York Mellon | 77k | $1.3M | -5% | Mar 2024 |
|
| Morgan Stanley | 63k | $1.1M | 86% | Mar 2024 |
|
| Exome Asset Management | 58k | $1.0M | 100% | Mar 2024 |
|
| Walleye Trading Advisors | 57k | $999k | 100% | Mar 2024 |
|
| BML Capital Management | 50k | $881k | 0% | Mar 2024 |
|
| Rhumbline Advisers | 38k | $672k | 2% | Mar 2024 |
|
| Swiss National Bank | 37k | $647k | 1% | Mar 2024 |
|
| Diametric Capital | 29k | $515k | 100% | Mar 2024 |
|
| UBS Group | 27k | $472k | 100% | Mar 2024 |
|
| Barclays | 26k | $462k | -38% | Mar 2024 |
|
| Blackstone Group | 25k | $443k | 100% | Mar 2024 |
|
| Blue Owl Capital Holdings | 25k | $440k | 100% | Mar 2024 |
|
| Exchange Traded Concepts | 25k | $434k | 184% | Mar 2024 |
|
| Credit Suisse | 22k | $385k | 0% | Mar 2024 |
|
| New York Life Investment Management | 20k | $356k | 100% | Mar 2024 |
|
| California State Teachers Retirement System | 19k | $337k | -11% | Mar 2024 |
|
| American Century Companies | 19k | $336k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 18k | $323k | -23% | Mar 2024 |
|
| Legal & General Group | 18k | $324k | -7% | Mar 2024 |
|
| Goldman Sachs Group | 17k | $304k | -24% | Mar 2024 |
|
| Bank of America Corporation | 17k | $294k | -46% | Mar 2024 |
|
| Alliancebernstein | 15k | $207k | 4% | Dec 2023 |
|
| State of Wisconsin Investment Board | 13k | $234k | -27% | Mar 2024 |
|
| Springbok Capital Management | 13k | $220k | 100% | Mar 2024 |
|
| MetLife Investment Advisors | 12k | $171k | 0% | Dec 2023 |
|
| American International | 12k | $161k | 0% | Dec 2023 |
|
| Deutsche Bank Aktiengesellschaft | 11k | $193k | 3% | Mar 2024 |
|
| Jane Street | 10k | $183k | -34% | Mar 2024 |
|
| SG Americas Securities | 9.4k | $166k | -30% | Mar 2024 |
|
| New York State Common Retirement Fund | 9.4k | $165k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 8.2k | $145k | 15% | Mar 2024 |
|
| China Universal Asset Management | 8.0k | $140k | 67% | Mar 2024 |
|
| Citigroup | 7.8k | $137k | 6% | Mar 2024 |
|
| Advisor Group Holdings | 2.0k | $35k | 0% | Mar 2024 |
|
| Summit Investment Advisors | 1.9k | $34k | 0% | Mar 2024 |
|
| Metropolitan Life Insurance Company | 1.3k | $18k | 0% | Dec 2023 |
|
| Royal Bank of Canada | 1.1k | $21k | -86% | Mar 2024 |
|
| Quest Partners | 850.00 | $15k | 100% | Mar 2024 |
|
| Amalgamated Bank | 787.00 | $14k | -61% | Mar 2024 |
|
| Tower Research Capital | 506.00 | $8.9k | -93% | Mar 2024 |
|
| Daiwa Securities Group | 152.00 | $3.0k | 100% | Mar 2024 |
|
| GAMMA Investing | 53.00 | $931.999700 | 43% | Mar 2024 |
|
| Baystate Wealth Management | 50.00 | $692.000000 | 0% | Dec 2023 |
|
| NISA Investment Advisors | 15.00 | $264.000000 | 67% | Mar 2024 |
|
| Russell Investments | 12.00 | $210.999600 | 0% | Mar 2024 |
|
| Pnc Financial Services | 8.00 | $141.000000 | 60% | Mar 2024 |
|
| Farther Finance Advisors | 6.00 | $112.999800 | 0% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 5.00 | $87.000000 | 100% | Mar 2024 |
|
| CWM | 4.00 | $0 | 100% | Mar 2024 |
|
| Covestor | 1.00 | $0 | 0% | Mar 2024 |
|
Who sold out of Enliven Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| JBF Capital | Sep 2023 | 27k | $369k |
| Bridgeway Capital Management | Sep 2023 | 18k | $245k |
| Mirae Asset Global Investments | Dec 2023 | 12k | $170k |
| Susquehanna International | Sep 2023 | 11k | $149k |
| AJOVista | Dec 2023 | 2.0k | $28k |